Literature DB >> 22817120

Occult hepatitis B virus infection in hemodialysis patients: a concept for consideration.

Arezoo Aghakhani1, Mohammad Banifazl, Ali Akbar Velayati, Ali Eslamifar, Amitis Ramezani.   

Abstract

Hemodialysis patients potentially have an increased risk of infection with parenterally transmitted viral agents due to an impaired host immune response and multiple transfusion requirements. Viral hepatitis is considered as a problem for hemodialysis patients because 1.9% of all deaths among this population are related to the consequence of viral hepatitis. Hepatitis B virus (HBV) is one of the most important causes of transmitted infections by the parenteral route in hemodialysis patients. Occult HBV infection is characterized by presence of HBV infection without detectable hepatitis B surface antigen (HBsAg), which harbors potential risk of HBV transmission through hemodialysis. There are conflicting reports on the prevalence of occult HBV infection (OBI) in hemodialysis patients. Considering the importance of occult HBV infection in hemodialysis patients and the growing evidence on this subject, the purpose of this review is to provide comprehensive information on OBI prevalence in hemodialysis patients and highlight the most important points in this issue.
© 2012 The Authors. Therapeutic Apheresis and Dialysis © 2012 International Society for Apheresis.

Entities:  

Mesh:

Year:  2012        PMID: 22817120     DOI: 10.1111/j.1744-9987.2012.01072.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  9 in total

1.  Prevalence of Occult Hepatitis B Virus Infection in Hemodialysis Patients Using Nested PCR.

Authors:  Elham Samadi; Hessam Mirshahabi; Nima Motamed; Hamid Sadeghi
Journal:  Rep Biochem Mol Biol       Date:  2020-04

Review 2.  Current hepatitis B virus infection situation in Indonesia and its genetic diversity.

Authors:  Maria Inge Lusida; Yoshihiko Yano
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

3.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18

4.  No evidence for occult HBV infection in hepatitis B vaccine non-responders.

Authors:  Mohammad Reza Aghasadeghi; Mohammad Banifazl; Arezoo Aghakhani; Ali Eslamifar; Rouhollah Vahabpour; Amitis Ramezani
Journal:  Iran J Microbiol       Date:  2014-10

5.  Isolated anti-hbc and occult HBV infection in dialysis patients.

Authors:  Amitis Ramezani; Mohammad Reza Aghasadeghi; Farrokhlagha Ahmadi; Effat Razeghi; Ali Eslamifar; Mohammad Banifazl; Masoomeh Sofian; Golnaz Bahramali; Soheila Hekmat; Arezoo Aghakhani
Journal:  Nephrourol Mon       Date:  2014-11-30

6.  Prevalence of overt and occult hepatitis B virus infections among 135 haemodialysis patients attending a haemodialysis centre at Al-Nasiriyah city, Iraq.

Authors:  Muslim Dhahr Musa; Hekmat Kadhum Ateya
Journal:  Iran J Microbiol       Date:  2020-10

7.  Viral Hepatitis and HIV Infection in Hemodialysis Patients.

Authors:  Arezoo Aghakhani; Mohammad Banifazl; Ali Eslamifar; Farrokhlagha Ahmadi; Amitis Ramezani
Journal:  Hepat Mon       Date:  2012-07-30       Impact factor: 0.660

8.  Occult hepatitis B infection in different high risk patients.

Authors:  Amitis Ramezani; Mohammad Banifazl; Ali Eslamifar; Masoomeh Sofian; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2012-07-30       Impact factor: 0.660

9.  Molecular Characterization of Pre-Core/Core and S Region of Hepatitis B Virus in Hemodialysis Patients With Occult Hepatitis B Infection.

Authors:  Nasrin Rastegarvand; Manoochehr Makvandi; Alireza Samarbafzadeh; Mojtaba Rasti; Niloofar Neisi; Amir Pouremamali; Ali Teimoori; Abdolnabi Shabani
Journal:  Jundishapur J Microbiol       Date:  2015-10-26       Impact factor: 0.747

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.